01dragonslayer
Veteran
- Aug 25, 2016
- 7,895
- 547
Overview
Both semaglutide and tirzepatide are FDA-approved medications for weight loss and diabetes management, but tirzepatide's dual-agonist mechanism offers distinct advantages.
Semaglutide (Ozempic, Wegovy)
Mechanism: GLP-1 receptor agonist
FDA Approval:
Ozempic (diabetes): 2017
Wegovy (weight loss): 2021
Average Weight Loss: 15-17% of body weight
Dosing: Weekly subcutaneous injection (0.25mg to 2.4mg)
Primary Benefits:
Significant weight loss
Improved glycemic control
Cardiovascular benefits
Reduced appetite
Slower gastric emptying
Tirzepatide (Mounjaro, Zepbound)
Mechanism: Dual GLP-1/GIP receptor agonist
FDA Approval:
Mounjaro (diabetes): 2022
Zepbound (weight loss): 2023
Average Weight Loss: 20-22% of body weight
Dosing: Weekly subcutaneous injection (2.5mg to 15mg)
Primary Benefits:
Superior weight loss vs semaglutide
Enhanced metabolic effects
Better glucose control
Improved insulin sensitivity
Potential muscle preservation
Head-to-Head Comparison
Feature Semaglutide Tirzepatide
Weight Loss 15-17% 20-22%
Mechanism GLP-1 only GLP-1 + GIP
Nausea Rate 20-30% 15-25%
Cost $$$ $$$$
Track Record Longer (2017) Newer (2022)
Muscle Preservation Moderate Better
A1C Reduction 1.5-2.0% 2.0-2.5%
Clinical Trial Results
STEP Trials (Semaglutide):
Average 15.3% weight loss at 68 weeks
86% achieved ≥5% weight loss
Significant cardiovascular benefits
SURMOUNT Trials (Tirzepatide):
Average 22.5% weight loss at 72 weeks
91% achieved ≥5% weight loss
Superior metabolic improvements
Side Effect Profile
Both Medications:
Nausea (most common, usually transient)
Diarrhea
Constipation
Abdominal pain
Fatigue
Tirzepatide Advantages:
Slightly lower nausea rates
Better GI tolerability in some patients
Contraindications (Both):
Personal/family history of medullary thyroid cancer
Multiple endocrine neoplasia syndrome type 2
Pregnancy/breastfeeding
Cost Considerations
Semaglutide:
Ozempic: ~$900-1,000/month
Wegovy: ~$1,300-1,400/month
Compounded: $200-400/month
Tirzepatide:
Mounjaro/Zepbound: ~$1,000-1,100/month
Compounded: $300-500/month
Which One to Choose?
Choose Semaglutide If:
Longer track record preferred
Lower cost is priority
Good results at lower doses
Insurance covers it
Choose Tirzepatide If:
Maximum weight loss desired
Better metabolic control needed
Muscle preservation important
Can tolerate higher cost
Combination with Other Peptides
Both can be stacked with:
BPC-157 (gut protection, muscle preservation)
CJC-1295/Ipamorelin (muscle maintenance)
NAD+ (metabolic support)
Conclusion
Semaglutide offers proven, significant weight loss with a longer safety track record.
Tirzepatide provides superior weight loss and metabolic benefits through its dual-agonist mechanism.
Both are excellent options—choice depends on individual goals, tolerance, and budget.
Both semaglutide and tirzepatide are FDA-approved medications for weight loss and diabetes management, but tirzepatide's dual-agonist mechanism offers distinct advantages.
Semaglutide (Ozempic, Wegovy)
Mechanism: GLP-1 receptor agonist
FDA Approval:
Ozempic (diabetes): 2017
Wegovy (weight loss): 2021
Average Weight Loss: 15-17% of body weight
Dosing: Weekly subcutaneous injection (0.25mg to 2.4mg)
Primary Benefits:
Significant weight loss
Improved glycemic control
Cardiovascular benefits
Reduced appetite
Slower gastric emptying
Tirzepatide (Mounjaro, Zepbound)
Mechanism: Dual GLP-1/GIP receptor agonist
FDA Approval:
Mounjaro (diabetes): 2022
Zepbound (weight loss): 2023
Average Weight Loss: 20-22% of body weight
Dosing: Weekly subcutaneous injection (2.5mg to 15mg)
Primary Benefits:
Superior weight loss vs semaglutide
Enhanced metabolic effects
Better glucose control
Improved insulin sensitivity
Potential muscle preservation
Head-to-Head Comparison
Feature Semaglutide Tirzepatide
Weight Loss 15-17% 20-22%
Mechanism GLP-1 only GLP-1 + GIP
Nausea Rate 20-30% 15-25%
Cost $$$ $$$$
Track Record Longer (2017) Newer (2022)
Muscle Preservation Moderate Better
A1C Reduction 1.5-2.0% 2.0-2.5%
Clinical Trial Results
STEP Trials (Semaglutide):
Average 15.3% weight loss at 68 weeks
86% achieved ≥5% weight loss
Significant cardiovascular benefits
SURMOUNT Trials (Tirzepatide):
Average 22.5% weight loss at 72 weeks
91% achieved ≥5% weight loss
Superior metabolic improvements
Side Effect Profile
Both Medications:
Nausea (most common, usually transient)
Diarrhea
Constipation
Abdominal pain
Fatigue
Tirzepatide Advantages:
Slightly lower nausea rates
Better GI tolerability in some patients
Contraindications (Both):
Personal/family history of medullary thyroid cancer
Multiple endocrine neoplasia syndrome type 2
Pregnancy/breastfeeding
Cost Considerations
Semaglutide:
Ozempic: ~$900-1,000/month
Wegovy: ~$1,300-1,400/month
Compounded: $200-400/month
Tirzepatide:
Mounjaro/Zepbound: ~$1,000-1,100/month
Compounded: $300-500/month
Which One to Choose?
Choose Semaglutide If:
Longer track record preferred
Lower cost is priority
Good results at lower doses
Insurance covers it
Choose Tirzepatide If:
Maximum weight loss desired
Better metabolic control needed
Muscle preservation important
Can tolerate higher cost
Combination with Other Peptides
Both can be stacked with:
BPC-157 (gut protection, muscle preservation)
CJC-1295/Ipamorelin (muscle maintenance)
NAD+ (metabolic support)
Conclusion
Semaglutide offers proven, significant weight loss with a longer safety track record.
Tirzepatide provides superior weight loss and metabolic benefits through its dual-agonist mechanism.
Both are excellent options—choice depends on individual goals, tolerance, and budget.
